NEW YORK (Reuters Health) Jan 22 - In men with prostate cancer, androgen-deprivation therapy (ADT) appears to increase the risk of subsequent diabetes, according to researchers.
As lead investigator Dr. Moe J. Lage told Reuters Health: “ADT is the hallmark strategy for prostate cancer patients with high risk of progressive disease or with advanced cancer, and we are still learning more about the metabolic consequences associated with this treatment.”
Dr. Lage of HealthMetrics Outcomes Research, LLC in Groton, Connecticut, and colleagues conducted a retrospective study using a claims database to compare 1231 prostate cancer patients treated with ADT with 7250 prostate cancer patients who did not undergo hormone treatment.
The team found that comorbidities, including hypertension and cardiovascular disease; demographic characteristics; prior statin use; and treatment with ADT all affected the probability of incident diabetes within 1 year.
After controlling for other factors, the estimated relative risk of incident diabetes associated with ADT was a significant 1.36.
“Future work should be conducted to examine the robustness of the results in other populations and for different time periods,” the investigators write in the December issue of Urology.
Meanwhile, Dr. Lage added, “The metabolic effects including increased risk of diabetes and metabolic syndrome should be considered” when treating men with prostate cancer, “along with the other more commonly recognized effects such as hot flashes and decreased libido and physiologic effects such as increased bone loss and muscle wasting.”